About BioEclipse Therapeutics
BioEclipse Therapeutics is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics. Its platform combines cytokine-induced killer (CIK) immune cells with an oncolytic vaccinia virus payload into a single, multi-mechanistic therapy designed to eradicate solid tumors and prevent relapse. Its lead drug candidate, CRX100, received FDA IND clearance in April 2020 and entered Phase 1 clinical trials targeting therapy-refractory solid tumors.
Company details
Funding
Total raised
$13.7M
Last stage
Seed
Investors
Founders
Chris Contag
Co-founder of BioEclipse Therapeutics (formerly ConcentRx Corp.) and previously co-founder of Xenogen Corporation. Holds 29+ patents across imaging, drug delivery, and immunotherapy.
Robert Negrin
Co-founder of BioEclipse Therapeutics.
Pamela Contag
Biopharmaceutical entrepreneur and researcher with 25+ years of experience. Co-founded BioEclipse Therapeutics (initially named ConcentRX), raising seed funding and licensing key patents from Stanford University. Named by Goldman Sachs as one of the 100 Most Intriguing Entrepreneurs of 2018.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.